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Abstract
Objective
Many cancer survivors are facing difficulties in getting a life insurance; raised premiums and
declinatures are common. We generated a prediction model estimating the conditional extra
mortality risk of breast cancer patients in the Netherlands. This model can be used by life
insurers to accurately estimate the additional risk of an individual patient, conditional on the
years survived.
Methodology
All women diagnosed with stage I-III breast cancer in 2005–2006, treated with surgery, were
selected from the Netherlands Cancer Registry. For all stages separately, multivariable
logistic regression was used to estimate annual mortality risks, conditional on the years sur-
vived, until 10 years after diagnosis, resulting in 30 models. The conditional extra mortality
risk was calculated by subtracting mortality rates of the general Dutch population from the
patient mortality rates, matched by age, gender and year. The final model was internally and
externally validated, and tested by life insurers.
Results
We included 23,234 patients: 10,101 stage I, 9,868 stage II and 3,265 stage III. The final
models included age, tumor stage, nodal stage, lateralization, location within the breast,
grade, multifocality, hormonal receptor status, HER2 status, type of surgery, axillary lymph
node dissection, radiotherapy, (neo)adjuvant systemic therapy and targeted therapy. All
models showed good calibration and discrimination. Testing of the model by life insurers
showed that insurability using the newly-developed model increased with 13%, ranging from
0%-24% among subgroups.
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Conclusion
The final model provides accurate conditional extra mortality risks of breast cancer patients,
which can be used by life insurers to make more reliable calculations. The model is expected
to increase breast cancer patients’ insurability and transparency among life insurers.
Introduction
Cancer incidence is rising, while mortality rates are decreasing[1,2]. The growing number of
cancer survivors aims to reintegrate into society, but encounters several problems. While sev-
eral studies focus on return to work[3–6], another major problem is the difficulty of getting a
life insurance, often needed for a mortgage, which is getting far less attention. A study on
socio-economic implications of cancer survivorship in the Netherlands, published in 2012,
showed that 60% of the applications for a life insurance by cancer survivors was declined[7]. In
the Netherlands, life insurers work with internationally available data on cancer survival to
estimate a patient’s mortality risk. These data can be different between insurance companies
and are not transparent due to life insurers’ competition policy. Providing life insurers identi-
cal data to base their decision on may enhance transparency. Besides, Dutch life insurers may
make better informed decisions by using data specifically addressing mortality risks for cancer
patients and survivors in the Netherlands.
Usually, survival is estimated from diagnosis, which is of limited value for cancer patients
who survived several years, since these estimates will be heavily influenced by patients who
died during the first years following diagnosis. It is more appropriate to have survival estimates
of patients who already survived the years that are relevant for the particular cancer patient
[8,9]. By estimating this so-called conditional survival, survival estimates are modified by only
including patients still alive at a relevant time point. As breast cancer is one of the most com-
monly diagnosed cancers in the world[10], this cancer type was selected to study conditional
survival in the Netherlands aiming to provide accurate data for life insurers. Conditional sur-
vival has been reported for many cancers, among others in breast cancer[8,11–16]. However,
prediction models estimating the conditional extra mortality risk, compared to the general
population, have not been generated yet. These types of models would not only provide life
insurers a better basis for their decision, it also provides medical experts a more objective basis
to deem a patient cured of disease[17].
This study aimed to generate a prediction model for breast cancer patients estimating the
annual extra mortality risk compared to the general population, conditional on zero to nine
years survived.
Materials and methods
Study population
We included all female operated patients diagnosed with stage I-III breast cancer in 2005–
2006 from the Netherlands Cancer Registry (NCR). This population-based registry contains
prospectively registered data on all patients newly diagnosed with cancer from 1989 onwards.
The NCR has specialized trained and dedicated registrars who derive patient-, tumor-, and
treatment-related characteristics from hospital records of all patients diagnosed with cancer.
This study was approved by the privacy committee (Commissie van Toezicht) of the NCR.
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Data collection
Data on patient-, tumor-, and treatment-related characteristics were obtained from the NCR.
Tumor topography and morphology were coded according to the International Classification
of Diseases for Oncology[18]. Staging was coded using the tumor, node, and metastasis classi-
fication system of the International Union Against Cancer, 6th edition[19]. Additional data on
vital status and date of death were derived from the Municipal Personal Records database and
were complete until February 2017.
Outcomes
The annual extra risks on mortality until 10 years after diagnosis, using conditional survival
points from zero to nine years. The extra risk was defined as the additional risk of a breast can-
cer patient at a specific time point after diagnosis, compared to the general population, calcu-
lated for stage I, II and III separately.
Statistical analysis
Patient-, tumor-, and treatment-related characteristics were summarized, separated by stage of
disease. Annual mortality risks, for every stage of disease, were calculated using conditional
logistic regression. This method was chosen as the outcomes of logistic regression can directly
be interpreted by life insurers as extra mortality risks per year, which can subsequently be trans-
lated into a premium. Conditional risks was estimated by excluding patients who had died at
start of every analysis (x years after diagnosis). Extra risks were calculated by subtracting the
risk of the general population by the risk of the patient population, where matching took place
on age, gender and calendar year. To match the patient population to the general population,
we calculated yearly risks (so they could be matched on calendar year). Accordingly, for each
stage of disease 10 models were generated calculating the 1-year mortality risk at diagnosis, and
one to nine years after diagnosis. Altogether, 30 models were generated. For each stage sepa-
rately, prognostic variables were included in the model when they significantly contributed to
one of the models (p<0.1). Prognostic variables could differ per stage of disease. Furthermore,
as occasionally the number of events was limited, some variables were reduced to less categories.
Variables included for analyses were: age, tumor stage, nodal stage, lateralization, location
within the breast, tumor differentiation grade, histological tumor type, multifocality, hormonal
receptor status (ER/PR status), HER2 status, type of surgery, axillary lymph node dissection, use
of adjuvant systemic therapy, primary systemic therapy, targeted therapy and radiotherapy. For
all patients the pathological tumor and nodal stages were used, except for patients treated with
primary systemic therapy, for who the clinical tumor and nodal stages were used. In case of a
re-excision, we used the most extensive operation as type of surgery. No stepwise, backward or
forward selection was performed, since these methods are shown to result in unstable and unre-
producible models and the selected variables are sensitive to random fluctuations in the data
[20]. Variance-covariance matrices were used to calculate 95% confidence intervals (CI).
Validation
Goodness-of-fit of each underlying model was determined by the Hosmer-Lemeshow test in
deciles based on the predicted risk. A non-significant test implied that the observed mortality
did not differ significantly from the predicted mortality risk[21]. Discriminatory accuracy was
determined by the Area Under the Receiver Operating Characteristic (ROC) curve (AUC). An
AUC of 0.5 indicates that the model is as good as flipping a coin, while an AUC of 1.0 repre-
sents perfect discriminatory accuracy.
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For every underlying model, internal validation was performed by manual bootstrapping
with 1000 replicates. The model was applied to every bootstrap sample, whereafter the AUC
was calculated. The difference between the original and the mean AUC of the 1000 replicates
was used as correction factor and subtracted from the original AUC. This bias-corrected AUC
was used as a measure for internal validation.
External validation was performed on patients diagnosed in 2007–2008, with the same
inclusion criteria as the development population. Only the first eight models of every stage
were externally validated, as follow-up for these patients was only completed until eight years
from diagnosis.
Model testing
Before the final model was made available for life insurers, the model was tested for its effect
on daily practice. This included the analysis of 50 patients per life insurer with specific charac-
teristics and number of years survived, based on randomly selected records from the NCR
(anonymized). In the Netherlands, there are 10 insurance companies specialized in life insur-
ances, which were all invited. Life insurers were asked to provide the mortality risks of the
patients based on the currently used guidelines (which differed among life insurers and were
confidential). These mortality risks were consequently translated into acceptation (with or
without premium raise) or rejection. All results were collected by the Centre for Insurance Sta-
tistics in the Netherlands, to comply with the Antitrust legislation, and subsequently anony-
mously provided to the Netherlands Comprehensive Cancer Organisation (IKNL). For every
stage of disease and age category, results of the newly-developed model were compared with
results of the currently used guidelines. Specification of the exact levels of premium raise was
not possible according to the Antitrust legislation. All statistical analyses were performed in
Stata/SE version 14.1 (StataCorp LP) and Microsoft Excel 2016.
Results
Study population
The study population comprised 23,234 patients. Patient-, tumor-, and treatment-related char-
acteristics per stage were summarized in Table 1. The mean age was 59 years (interquartile
range 49–69 years). Most patients were diagnosed with stage I disease (43.5%) (Table 1).
Median follow-up from date of diagnosis to date of last observation was 10.6 years (interquar-
tile range 8.7 to 11.3 years).
Prediction models
For all underlying models estimating the mortality risk for stage I, we selected the following pre-
dictive variables: age, location within the breast, tumor differentiation grade, histological tumor
type, multifocality, hormonal receptor status (ER/PR status), HER2 status, type of surgery, axil-
lary lymph node dissection, use of adjuvant systemic therapy, primary systemic therapy, tar-
geted therapy and radiotherapy. For the underlying models estimating the mortality risk for
stage II, we selected the same predictive variables as for stage I, but added the variables tumor
stage and nodal stage. For the underlying models predicting the mortality risk for stage III, the
same predictive variables as for stage II were used. All 30 underlying models, including the 95%
CIs, were embedded in a prediction model which is available on https://predictiemodel.
verzekeraars.nl. A screenshot of the prediction model, currently available in Dutch, is shown in
S1 Fig.
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Table 1. Patient-, tumor-, and treatment-related characteristics.
Characteristics Stage I (n = 10,101) Stage II (n = 9,868) Stage III (n = 3,265)
Age (years)
<40 405 (4.0) 657 (6.7) 261 (8.0)
40–64 5,978 (59.2) 5,804 (58.8) 1,959 (60.0)
�65 3,718 (36.8) 3,407 (34.5) 1,045 (32.0)
Pathological tumor stage
T1 10,051 (99.5) 3,037 (30.8) 666 (20.4)
T2 - 6,516 (66.0) 1,351 (41.4)
T3 - 273 (2.8) 646 (19.8)
T4 - - 569 (17.4)
Unknown 50 (0.5) 42 (0.4) 33 (1.0)
Pathological nodal stage
N0 9,835 (97.4) 3,960 (40.1) 154 (4.7)
N1 - 5,761 (58.4) 613 (18.8)
N2 - - 1,571 (48.1)
N3 - - 886 (27.1)
Unknown 266 (2.6) 147 (1.5) 41 (1.3)
Location
Outer quadrants 4,740 (46.9) 4,702 (47.7) 1,420 (43.5)
Inner quadrants 2,221 (22.0) 1,724 (17.5) 379 (11.6)
Central parts 623 (6.2) 751 (7.6) 313 (9.6)
Overlapping lesions 2,296 (22.7) 2,517 (25.5) 1,068 (2.6)
Unknown 221 (2.2) 174 (1.8) 85 (2.6)
Differentiation grade
Well 2,979 (29.5) 1,558 (15.8) 289 (8.9)
Moderate 4,424 (43.8) 4,206 (42.6) 1,132 (34.7)
Poor 2,109 (20.9) 3,431 (34.8) 1,399 (42.9)
Unknown 589 (5.8) 673 (6.8) 445 (13.6)
Histological tumor type
Ductal 8,231 (81.5) 7,857 (79.6) 2,523 (77.3)
Lobular 896 (8.9) 1,214 (12.3) 516 (15.8)
Mixed 408 (4.0) 393 (4.0) 163 (5.0)
Other 566 (5.6) 404 (4.1) 63 (1.9)
Multifocality
No 8,528 (84.4) 8,069 (81.8) 2,370 (72.6)
Yes 1,255 (12.4) 1,554 (15.8) 756 (23.2)
Unknown 318 (3.2) 245 (2.5) 139 (4.3)
Hormonal receptor status
ER and PR positive 6,887 (68.2) 6,331 (64.2) 1,811 (55.5)
ER or PR positive 1,631 (16.2) 1,581 (16.0) 605 (18.5)
ER negative 1,286 (12.7) 1,888 (19.1) 837 (25.6)
Unknown 297 (2.9) 68 (0.7) 12 (0.4)
HER2 status
Negative 7,464 (73.9) 7,444 (75.4) 2,281 (69.9)
Unclear 938 (9.3) 354 (3.6) 85 (2.6)
Positive 950 (9.4) 1,457 (14.8) 682 (20.9)
Unknown 749 (7.4) 613 (6.2) 217 (6.7)
Type of surgery
(Continued)
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Validation
All goodness-of-fit tests for all underlying models were non-significant, indicating no signifi-
cant difference between observed and predicted mortality (Table 2). Discrimatory accuracy
was moderate to good for all models with AUCs ranging from 0.69–0.90 (Table 2). After boot-
strapping, the bias-corrected AUCs ranged from 0.67–0.88 (Table 2), indicating moderate to
good discriminatory accuracy for all underlying models as a measure for internal validation.
Table 1. (Continued)
Characteristics Stage I (n = 10,101) Stage II (n = 9,868) Stage III (n = 3,265)
Breast-conserving surgery 6,956 (68.9) 4,670 (47.3) 731 (22.4)
Mastectomy 3,137 (31.1) 5,194 (52.6) 2,533 (77.6)
Unknown 8 (0.1) 4 (0.0) 1 (0.0)
Axillary lymph node dissection
No 8,544 (84.6) 3,364 (34.1) 116 (3.6)
Yes 1,557 (15.4) 6,504 (65.9) 3,149 (96.5)
Radiotherapy
No 3,208 (31.8) 4,501 (45.6) 436 (13.4)
Yes 6,893 (68.2) 5,367 (54.4) 2,829 (86.7)
Adjuvant systemic therapy
No 8,012 (79.3) 1,808 (18.3) 532 (16.3)
Endocrine therapy 883 (8.7) 3,440 (34.9) 851 (26.1)
Chemotherapy 564 (5.6) 1,416 (14.4) 562 (17.2)
Both 642 (6.4) 3,204 (32.5) 1,320 (40.4)
Primary systemic therapy
No 10,055 (99.5) 9,322 (94.5) 2,659 (81.4)
Yes 46 (0.5) 546 (5.5) 606 (18.6)
Targeted therapy
No 9,853 (97.5) 8,936 (90.6) 2,756 (84.4)
Yes 248 (2.5) 932 (9.4) 509 (15.6)
Numbers are n (%). Abbreviations: ER = estrogen receptor, PR = progesterone receptor, HER2 = human epidermal growth factor receptor.
https://doi.org/10.1371/journal.pone.0210887.t001
Table 2. Overview of the Hosmer-Lemeshow test, the AUC and the bias-corrected AUC as measures for goodness-of-fit, discriminatory accuracy and internal vali-
dation of the models.
Stage I (n = 10,101) Stage II (n = 9,868) Stage III (n = 3,265)
Model
HL test
p-value
AUC Bias-corrected AUC HL test
p-value
AUC Bias-corrected AUC HL test
p-value
AUC Bias-corrected AUC
Year 0–1 0.499 0.81 (0.76–0.86) 0.79 (0.73–0.89) 0.087 0.86 (0.84–0.89) 0.85 (0.76–0.90) 0.351 0.90 (0.88–0.93) 0.89 (0.77–0.94)
Year 1–2 0.896 0.76 (0.72–0.79) 0.75 (0.69–0.81) 0.190 0.80 (0.78–0.82) 0.79 (0.75–0.83) 0.539 0.83 (0.80–0.85) 0.81 (0.77–0.86)
Year 2–3 0.883 0.74 (0.71–0.76) 0.73 (0.67–0.79) 0.577 0.75 (0.73–0.77) 0.74 (0.70–0.78) 0.089 0.77 (0.75–0.79) 0.75 (0.70–0.80)
Year 3–4 0.251 0.72 (0.69–0.74) 0.70 (0.65–0.76) 0.601 0.75 (0.74–0.76) 0.74 (0.70–0.79) 0.385 0.74 (0.72–0.76) 0.72 (0.65–0.78)
Year 4–5 0.679 0.71 (0.68–0.73) 0.70 (0.65–0.75) 0.291 0.71 (0.69–0.72) 0.70 (0.65–0.75) 0.190 0.74 (0.72–0.76_ 0.71 (0.66–0.78)
Year 5–6 0.229 0.70 (0.67–0.72) 0.68 (0.63–0.74) 0.944 0.73 (0.72–0.75) 0.72 (0.67–0.77) 0.713 0.73 (0.72–0.74) 0.69 (0.60–0.77)
Year 6–7 0.579 0.72 (0.70–0.75) 0.70 (0.65–0.76) 0.644 0.73 (0.72–0.74) 0.72 (0.66–0.77) 0.286 0.71 (0.69–0.73) 0.67 (0.58–0.74)
Year 7–8 0.746 0.68 (0.66–0.70) 0.67 (0.62–0.72) 0.513 0.71 (0.70–0.73) 0.70 (0.64–0.78) 0.203 0.74 (0.72–0.76) 0.70 (0.64–0.78)
Year 8–9 0.291 0.74 (0.72–0.76) 0.73 (0.68–0.78) 0.595 0.74 (0.73–0.75) 0.73 (0.68–0.78) 0.231 0.73 (0.71–0.75) 0.69 (0.60–0.76)
Year 9–10 0.632 0.71 (0.69–0.72) 0.70 (0.65–0.76) 0.572 0.77 (0.76–0.79) 0.76 (0.71–0.81) 0.178 0.72 (0.70–0.74) 0.68 (0.59–0.78)
Abbreviations: HL = Hosmer-Lemeshow; AUC = Area under the receiver operating characteristic curve.
https://doi.org/10.1371/journal.pone.0210887.t002
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For external validation on patients diagnosed in 2007–2008, 24,761 patients were included
of who 11,227 (45.3%) had stage I, 10,410 (42.0%) stage II and 3,124 (12.6%) stage III. Baseline
characteristics of this validation population are shown in S1 Table. The external validation
showed good calibration for all models. Calibration was expressed as the expected percentage
of mortality using the newly-developed model minus the observed percentage of mortality in
the validation population. Although several models showed a statistically significant difference
between expected and observed mortality, the percentages were very small (<2% for 1 model,
<1% for all other models). Discriminatory accuracy was moderate to good for all models with
AUCs ranging from 0.61–0.87 (Table 3). As we know that breast cancer subtypes play an
important role in breast cancer prognosis, we additionally performed the validation for ER
positive, HER2 positive and triple negative breast cancer patients. Calibration of the model
was satisfying in all three groups, with differences between expected and observed mortality
under 3% (S2–S4 Tables). Discriminatory accuracy was moderate to good for ER positive
breast cancer patients (AUCs ranging from 0.63 to 0.84) (S2 Table). For HER2 positive and tri-
ple negative patients, the AUCs for most of the models were moderate to good, but several
models showed poor discriminatory accuracy (with wide confidence intervals), caused by the
low numbers of events in these years (S3 and S4 Tables).
Model testing
Altogether, eight of the 10 life insurers responded. Fig 1 summarizes the insurability of the 50
cases for every stage and age category. Overall, the insurability increased from 43%-56%. How-
ever, the lower number of declined applications resulted in a higher number of accepted appli-
cations with temporary or permanent premium raises. The number of applications accepted at
standard rates decreased from 8%-4%. Patients aged 40–64 and patients with stage III breast
cancer benefited the most of the newly-developed model compared to the currently used
guidelines: insurability (with or without premium raise) increased from 44%-62% and from
21%-45%, respectively.
Results were further specified for the age groups <40 and 40–64 years (for the group�65
years numbers were too small) (Fig 2). For all (ex-)patients<40 years, the percentage of rejec-
tions decreased by using the newly-developed model. As more patients were accepted,
Table 3. Calibration and discrimination of the model on the external validation population (2007–2008, n = 24,761).
Stage I (n = 11,227) Stage II (n = 10,410) Stage III (n = 3,124)
Model Expected–observed (95% CI) AUC Expected–observed (95% CI) AUC Expected–observed (95% CI) AUC
Year 0–1 0.28 (0.26–0.30) 0.71 (0.65–0.78) -0.10 (-0.12 to -0.08) 0.87 (0.75–0.82) -0.80 (-0.84 to -0.76) 0.86 (0.83–0.90)
Year 1–2 -0.66 (-0.68 to -0.64) 0.68 (0.64–0.72) 0.31 (0.29–0.34) 0.76 (0.73–0.79) -0.26 (-0.30 to -0.22) 0.81 (0.77–0.84)
Year 2–3 -0.11 (-0.13 to -0.09) 0.66 (0.62–0.70) 0.30 (0.28–0.32) 0.72 (0.69–0.75) -0.21 (-0.25 to -0.17) 0.74 (0.70–0.78)
Year 3–4 0.44 (0.42–0.46) 0.65 (0.60–0.69) -0.28 (-0.30 to -0.26) 0.69 (0.66–0.72) -0.40 (-0.44 to -0.36) 0.69 (0.65–0.73)
Year 4–5 -0.73 (-0.75 to -0.71) 0.63 (0.59–0.67) -0.17 (-0.19 to -0.15) 0.70 (0.67–0.73) 0.19 (0.15–0.24) 0.61 (0.56–0.66)
Year 5–6 -0.02 (-0.04 to 0.00) 0.67 (0.64–0.71) 0.53 (0.51–0.55) 0.70 (0.67–0.73) -0.06 (-0.10 to -0.01) 0.66 (0.60–0.71)
Year 6–7 0.14 (0.12–0.16) 0.69 (0.65–0.72) 0.07 (0.05–0.09) 0.69 (0.66–0.73) 1.51 (1.46–1.56) 0.68 (0.62–0.74)
Year 7–8 -0.11 (-0.13 to -0.09) 0.66 (0.63–0.70) 0.46 (0.44–0.49) 0.70 (0.66–0.74) 0.94 (0.89–0.98) 0.64 (0.58–0.74)
Year 8–9 - - - - - -
Year 9–10 - - - - - -
Calibration is expressed as the expected mortality of the newly-developed model minus the observed mortality, both in percentages, in the validation population.
Validation of the last two models per stage was not possible due to lack of follow-up after eight years. Abbreviations: AUC = area under the receiver operating
characteristic curve.
https://doi.org/10.1371/journal.pone.0210887.t003
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temporary or permanent premium increases were more common. For patients<40 years with
stage II disease, the number of acceptations at standard rates decreased from 5%-0%. (Ex-)
patients age<40 with stage III breast cancer benefit the most from the new model, with accep-
tance rates increasing from 13% using the current guidelines to 34% with the newly-developed
model. (Ex-)patients aged 40–64 with stage I disease showed the least benefit of the newly-
developed model. The number of rejections remained identical, but the number of accepta-
tions at standard rates declined from 34%-11% using the new model. However, acceptance
rates were for this group the highest, namely 86%. For patients aged 40–64 with stage II and III
disease, the newly-developed model showed less rejections, and the number of acceptations at
standard rates remained similar.
Discussion
A conditional prediction model for the annual extra mortality risk of breast cancer patients
compared to the general population was generated. This prediction model provides life
Fig 1. Comparison of insurability of (ex-)breast cancer patients between currently used guidelines (A) and the newly-developed model (B).
https://doi.org/10.1371/journal.pone.0210887.g001
Fig 2. Further specification of the comparison of insurability of (ex-)breast cancer patients between current guidelines (A) and the newly-developed model (B).
https://doi.org/10.1371/journal.pone.0210887.g002
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insurers with more reliable information to base their decision on, which is shown to result in
increased insurability of breast cancer patients in a test using 50 random patients.
The benefit of the newly-developed model in terms of insurability was greatest for patients
with stage III breast cancer. Especially for (ex-)patients<40 years with stage III disease,
insurability was almost tripled. This is of great importance as this group mostly applies for a
life insurance, as part of a mortgage. For patients with stage I disease, the newly-developed
model did not add much benefit in terms of insurability. This may be explained by the fact
that higher staged breast cancers, when recurring, most often recur in the first few years fol-
lowing diagnosis[22]. Being alive an increasing number of years following diagnosis consider-
ably lowers the remaining risk on locoregional recurrences and distant metastases and
consequently the risk of death.
As this model is specifically designed for the number of years survived, it provides life
insurers enhanced insight in increasing survival probabilities over time, resulting in a higher
chance to get accepted. The higher acceptance rates were mainly acceptances with premium
increases, as patients whose applications were first rejected are now mostly accepted against a
raised premium. The exact premium raise could not be specified due to life insurers’ competi-
tion policy, the Antitrust legislation, and the relatively low number of tested cases. However,
these premium raises varied widely between life insurers. Some patients were first accepted at
standard rates, but had to pay a premium raise using the newly-developed model. Fortunately,
these raises were low and may not outweigh the increased number of acceptations. Further-
more, an application of a specific patient which is rejected by one life insurer may be accepted
by another. Although our model provides a more objective basis for life insurers to base their
decision on, it does not change the large differences in the consequences for the premium. We
showed that for patients aged 40–64 with stage I disease, the number of acceptations at stan-
dard rates decreased from 34%-11% using the new model. Notably, every life insurer tested the
model on the same 50 cases, so results are presented at the level of the life insurers, and not on
individual level. A sensitivity analysis of the data showed that, when individual patients would
apply at multiple life insurers, every patient in this test was insurable (either at standard rates
or with premium raises). This information should, however, be cautiously interpreted, as pre-
miums are sometimes very high. Therefore, breast cancer patients and survivors–especially
patients aged 40–64 with stage I disease–are advised to apply for a life insurance at different
life insurers, and to compare the outcomes.
Multiple prediction models for breast cancer have been developed, of which many predict
the overall mortality risk[23–27]. One of these models, the Breast Cancer Conditional Out-
come Calculator (CancerMath.net)[26], estimates conditional survival, thereby increasing its
usability for patients who survived several years. Accuracy of this model was considered to be
modest in Southeast Asian women with breast cancer[28]. This model, however, does not pro-
vide the annual mortality risks and does not show uncertainty around the estimates. Especially
the latter is important, since communication of risk prediction models to patients is shown to
be very difficult[29].
Our study has several strengths. First, we corrected patients’ mortality rates for the mortal-
ity rates of the general Dutch population. Herewith, more information on a patient’s individual
extra risk is provided. Second, we used the NCR to cover the entire Dutch breast cancer popu-
lation, thereby enhancing the generalizability of the model. Third, a large number of patients
(n = 23,234) was included, allowing us to include a large number of predictive factors. The
NCR has a completeness of over 95% and is considered to be of high quality due to very
tumor-specific guidelines, trained data managers and regular quality controls. This data is
therefore representative for the entire non-metastatic breast cancer population. A limitation is
the lack of knowledge on performance status or comorbidities. Irrespective of a previous
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cancer diagnosis, comorbidity may lead to a lower chance to be insured. Furthermore, cancer
patients with comorbidities are less likely to receive the standard cancer treatments, and their
risk of postoperative complications is higher compared to patients without comorbidities,
resulting in lower overall survival rates[30–32]. However, by adjusting the observed mortality
for the expected mortality risks of the general population, matched by age, gender and calen-
dar year, we partly solved this problem by correction for age- and gender-related comorbidi-
ties. Furthermore, we lacked data on recurrences during follow-up. This might lead to an
overestimated mortality risk for patients who are free of disease during follow-up and an
underestimated mortality risk for patients diagnosed with a recurrence during follow-up.
Another limitation is the use of the general Dutch population as a reference. Baseline mortality
risks of other countries may differ from those in the Netherlands, which may have conse-
quences for the applicability of this model in other countries. Therefore, before using this
model on a specific target population, the model should be validated on that population. Pre-
dictive modelling in general has limitations, as the risk produced by a certain model is based
on an underlying model population with certain characteristics that are most often collected
retrospectively. These patients have been treated according to clinical guidelines that were
valid at time of diagnosis, which is in this case over 10 years ago. One can imagine that results
of this specific underlying population may be different in future patients. Besides, since two
patients with exactly similar characteristics may respond completely different on a certain
treatment, it should be communicated to patients that the risk produced by the model does
not have to count for them per se. Therefore, it is vital to take any other prognostic informa-
tion into account, such as development of new therapies and outcomes of randomized con-
trolled trials. Lastly, life insurances often last for 30 years. Our model only includes
information until 10 years from diagnosis. As a very important prognostic factor–the HER2
status–was introduced in 2005, and patients were also treated accordingly, it was decided not
to include patients diagnosed before 2005. The fact we included the more contemporary treat-
ment regimens and important knowledge on receptor statuses outweighs in our opinion the
limited follow-up time. Lastly, several aspects on data interpretation have to be discussed.
Although a large number of patients is included, outcomes of very specific combinations of
variables in a specific year following diagnosis may still be hard to interpret, as they may some-
times reflect a low number of cases and events. For this reason, it is of crucial importance to
evaluate the confidence intervals around the estimates. If these are very wide, one should be
careful in interpreting the results, as a certain outcome may be due to chance. Results of this
model are not meant to directly be translated into raises of premium, but they are there to sup-
port life insurers in their decision. Any other information, such as the use of new therapies,
presence of comorbidities or recent literature should be taken into account.
The Dutch Association of Insurers stimulates the use of the model by life insurers by pro-
viding information on their website and in several meetings. The model is currently being
used by several Dutch life insurers in practice, who are documenting both the results of the
new model and that of their current guidelines for a year, for every (ex-)breast cancer patient
who applies for a life insurance. After a year, these results will be evaluated and consequently
used for improving the model or identification of any remaining problems.
The results of our study are not directly applicable to other countries, as we specifically gen-
erated this model for patients diagnosed with breast cancer in the Netherlands (including the
use of a Dutch reference population), to optimize the decision-making process in the applica-
tion for a life insurance. The model can, of course, be validated on other populations to deter-
mine its accuracy. However, with this model we hope to active other researchers in other
countries to generate a similar model for their own population. As many (ex-)cancer patients
from many countries are still experiencing difficulties in getting a life insurance, it is of crucial
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importance to use representative and up to date information on extra mortality risks. Creating
a prediction model on the same population as were it is applied on results in the most accurate
predictions.
Conclusions
In this study, a conditional prediction model for the annual extra mortality risk of breast can-
cer patients compared to the general population was generated. This model was internally and
externally validated and was tested in practice with satisfying results. The model is publicly
available and ready to be used by life insurers in the Netherlands. By providing all life insurers
the same base for their decision, we hope to increase transparency to patients. For a year, all
applications by breast cancer patients and survivors will be processed by life insurers using
both the current guidelines and the newly-developed model. Thereafter, the results will be ana-
lyzed and included in further discussions on insurability of breast cancer patients and survi-
vors between the Dutch Federation of Cancer Patient Organizations and the Dutch
Association of Insurers. Furthermore, the model will be updated regularly, to ensure that life
insurers work with the most recent and reliable data. In future, prediction models for other
types of cancers will be developed.
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